Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019;10(1):2977.

Toyoda Y, Franck P, Brownstone ND, Lieberman M, Magro CM, Otterburn DM. Apocrine adenocarcinoma in the setting of apocrine hidrocystoma of the leg. Dermatol Online J. 2019;25(6).

Krishnamoorthy GP, Davidson NR, Leach SD, Zhao Z, Lowe SW, Lee G, et al. and Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC. Cancer Discov. 2019;9(2):264-281.

Caslini C, Hong S, Ban YJ, Chen XS, Ince TA. HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells. Oncogene. 2019;38(39):6599-6614.

Labbé DP, Zadra G, Yang M, Reyes JM, Lin CY, Cacciatore S, et al. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nat Commun. 2019;10(1):4358.

Mueller FB, Yang H, Lubetzky M, Verma A, Lee JR, Dadhania DM, et al. Landscape of innate immune system transcriptome and acute T cell-mediated rejection of human kidney allografts. JCI Insight. 2019;4(13).

Augello MA, Liu D, Deonarine LD, Robinson BD, Huang D, Stelloo S, et al. CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer Cell. 2019;35(4):603-617.e8.

Vossoughi S, Gorlin J, Kessler DA, Hillyer CD, Van Buren NL, Jimenez A, et al. Ten years of TRALI mitigation: measuring our progress. Transfusion. 2019;59(8):2567-2574.

Penney KL, Loda M, Stampfer MJ. Re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eu. Eur Urol. 2019;75(3):e54-e55.

Cushing MM, DeSimone RA, Goel R, Hsu Y-, Parra P, Racine-Brzostek SE, et al. The impact of Daratumumab on transfusion service costs. Transfusion. 2019;59(4):1252-1258.